Prof. Pengtao Liu graduated from Henan Normal University and earned his Master of Science degree from Chinese Academy of Sciences/University of Science and Technology of China. He received his PhD from Baylor College of Medicine under the guidance of Professor Allan Bradley, and completed his postdoctoral training at National Cancer Institute (USA) in the laboratories of Dr. Neal Copeland and Dr. Nancy Jenkins. Dr. Liu joined the Wellcome Trust Sanger Institute in September 2003. He initiated the high-throughput recombineering for the large-scale mouse mutagenesis programme at the Sanger Institute. Dr. Liu's laboratory has identified the critical roles of transcription factors, Bcl11a and Bcl11b, in hematopoietic stem cells, in lymphocyte development, and in mammary gland development. By mutating Bcl11b, they have discovered that T lymphocytes are reprogrammed to a new type of cancer killer cells. Dr. Liu's lab has also identified that BCL11A is an important cancer gene in triple negative breast cancer. Dr. Liu's lab also studies pluripotent stem cells, and the mechanisms of reprogramming somatic cells to iPS cells. His group is the first to demonstrate CRISPR editing in iPS cell generation. Website: http://www.sbms.hku.hk/staff/pengtao-liu